Stockscreener 앱 받기
10.99
0.37%
0.04
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Moving Averages: Will Norfolk Southern Corporation outperform tech stocksJuly 2025 Catalysts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Ex-Biotech CEO Cashed In $10M Ahead Of COVID Vaccine Crisis: Lawsuit - AOL.com
JPM movers: ImmunityBio rises to the top - BioCentury
FRAUD AND MANIPULATION—N.Y. Sup.: New York’s AG sues former Emergent BioSolutions CEO for insider trading - VitalLaw.com
Insider Sell: Can BOS Better Online Solutions Ltd disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Retail Trends: Is CMREPRC stock technically oversoldEarnings Trend Report & Daily Price Action Insights - baoquankhu1.vn
Lobbying Update: $430,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Quiver Quantitative
New York Sues Former C.E.O. of Covid Vaccine Maker Over Insider Trading - The New York Times
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading - BioPharma Dive
Emergent BioSolutions (EBS) Receives a New Order from US Department of War - Insider Monkey
Former biotech CEO sued over COVID vaccine alleged insider trading - AOL.com
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement - Intellectia AI
Read This Before Judging Emergent BioSolutions Inc.'s (NYSE:EBS) ROE - Yahoo Finance
Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 23% Upside Potential and Robust Free Cash Flow - DirectorsTalk Interviews
Ex-CEO sued by New York for insider trading tied to COVID-19 vaccine contamination - 1470 & 100.3 WMBD
New Packaging Option for Narcan Nasal Spray Aims to Reduce Stigma - Psychiatry Advisor
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading - Law360
Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO - Stocktwits
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading - The Wall Street Journal
Ex-CEO sued by New York for insider trading tied to COVID vaccine contamination - Reuters
NY Sues Ex-Emergent BioSolutions CEO for Insider Trading (1) - Bloomberg Law News
Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4%What's Next? - MarketBeat
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update - marketscreener.com
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline - Sahm
Emergent BioSolutions makes $100 million voluntary loan prepayment By Investing.com - Investing.com Nigeria
Emergent BioSolutions Inc CEO Presents at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet? - 富途牛牛
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness - The Manila Times
FDA clears discreet NARCAN case to help more people carry overdose spray - Stock Titan
Emergent BioSolutions, Inc. Announces Voluntary Prepayment of $100 Million Under its Outstanding Term Loan Facility - marketscreener.com
Emergent BioSolutions Announces $100 Million Loan Paydown - citybiz
Emergent BioSolutions makes $100 million voluntary loan prepayment - Investing.com
Emergent BioSolutions Inc Announces $100 Million Term Loan Prepayment - TradingView — Track All Markets
Emergent BioSolutions announces $100 million paydown of term loan principal, a significant step achieved toward its multi-year transformation - marketscreener.com
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation - The Manila Times
Star Tribune - FinancialContent
Market Review: Is Emergent BioSolutions Inc currently under institutional pressureJuly 2025 Short Interest & Weekly Momentum Stock Picks - baoquankhu1.vn
Published on: 2026-01-10 21:10:13 - Улправда
Will Emergent BioSolutions Inc. stock gain from government policiesJuly 2025 Trends & Accurate Entry and Exit Point Alerts - Улправда
Will Emergent BioSolutions Inc. stock maintain growth storyQuarterly Trade Summary & Community Driven Trade Alerts - Улправда
Can Emergent BioSolutions Inc. stock rebound after recent weaknessMarket Volume Summary & Stock Timing and Entry Methods - ulpravda.ru
Emergent BioSolutions (EBS) Secures $21.5M U.S. Defense Order fo - GuruFocus
Emergent BioSolutions Receives $21.5 Million Delivery Order for BioThrax - marketscreener.com
Emergent BioSolutions receives $21.5 million order from U.S. Department of War to supply Biothrax in 2026 - marketscreener.com
Emergent BioSolutions Secures $21.5 Million Order for BioThrax® Anthrax Vaccine from U.S. Department of War - Quiver Quantitative
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 - The Spec
Emergent BioSolutions partners with PANTHER on mpox treatment trial By Investing.com - Investing.com Canada
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa - The Manila Times
EBS (NYSE: EBS) insider files notice to sell 25,748 common shares - Stock Titan
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
1.30%
1.45%
자본화:
|
볼륨(24시간):